ARTICOLO ORIGINALE   

La Rivista Italiana della Medicina di Laboratorio 2019 Giugno;15(2):128-31

DOI: 10.23736/S1825-859X.19.00011-2

Copyright © 2019 EDIZIONI MINERVA MEDICA

lingua: Inglese

The papillomavirus (HPV) might have a key role in benign and malignant prostate lesions

Angela GIANNATTASIO ¹ ✉, Maria R. BUONAIUTO ¹, Angela TEDESCO ¹, Pasqualina RAFFIO ¹, Anna BASILE ¹, Romilda MINICHINI ¹, Claudio A. BALIANO ¹, Francesco FRANZESE ², Giuliana CANONICO ³, Erika SICILIANO ¹, Giovanni GALANO ¹, Maria T. POLISTINA ¹

¹ Unità Complessa Laboratorio Analisi di Patologia, PSI Napoli Est, ASL Napoli 1 Centro, Napoli, Italia; ² Unità di Urologia, PSI Napoli Est, ASL Napoli 1 Centro, Napoli, Italia; ³ Unità Operativa Complessa Laboratorio Analisi e Tossicologia, Unità Medica Multifunzionale Loreto Crispi, ASL Napoli 1 Centro, Napoli, Italia

BACKGROUND: The aim of this paper was to show the role of the papillomavirus (HPV) in benign and malignant prostate lesions, especially in malignant. HPV is a DNA virus related to cervical carcinoma; a lot of reports, in literature, confirm that there is a relationship between HPV and other cancers: oral cancer, skin cancer, and some types of lung cancer. At the moment men are not only HPV “bearer” but HPV causes about half of all penile cancers and nearly all anal carcinomas, half of which occur in men.
METHODS: We examined 30 patients with pre-cancerous and/or cancerous lesions. DNA extraction was carried out from paraffined tissue of prostatic glands. Subsequently an amplification of a 450 bp, HPV specific L1 gene, was performed with the MY09/11 consensus primers (HPV Screening L1- NanoGen Advanced Diagnostics). The PCR products were revealed on the agarose gel and genotyped with reverse hybridization on nitrocellulose strips. This test for HPV genotypes identification was based on amplification of a part of L1 viral region (450 bp) by polymerase-chain-reaction (PCR) using the primers MY09- MY10, while a shorter sequence (150 bp) was obtained by nested PCR, using the primers GP5-GP6 and involves genotyping strip of 40 HPV types (ABAnalitica®-Advanced Biomedicine).
RESULTS: On 30 patients examined, we detected the presence of HPV High Risk (HR-HPV) in 14 samples with positive biopsy for malignant cells (Gleason Score 2-5), in 3 patients with prostatitis we detected HPV 6 (Low Risk), 4 patients, with a prostatic carcinoma (Gleason Score 6-8), were HPV negative, and 9 patients were negative for HPV and histological diagnosis.
CONCLUSIONS: The results show that HPV infection could play a key role in benign and malignant lesions of the prostate, and not only in cervix cancer; therefore the HPV screening and genotyping might be fundamental also in man. Further studies are needed to confirm the results obtained.

KEY WORDS: Human papillomavirus; Prostate; Neoplasms